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In the previous issue of Critical Care, Chase and 
colleagues present retrospective, historically controlled 
data from 784 critically ill patients treated with tight 
glycemic control (target glucose, 4 to 6 mmol/l) using the 
Specialised Relative Insulin and Nutrition Titration 
(SPRINT) protocol [1]. Th   ey report achieving faster reso-
lu  tion of organ failure. Th  is observation dovetails with 
the Leuven I trial [2] and early studies [3,4] that ﬁ  rst 
showed reductions in the incidence of renal and respira-
tory failure, but conﬂ  icts with other more recent trials 
demonstrating no diﬀ  erence in organ failure when using 
intensive insulin [5-10].
Th   e main advantages of SPRINT are that the protocol 
aims for relatively strict euglycemia, the protocol is con-
ser  vative in application, the protocol maintains eugly-
cemia with less variability, the protocol concomi  tantly 
adjusts for caloric intake using a handheld device 
protocol for insulin dosing, and the protocol requires 
frequent blood glucose monitoring. Th  e ﬁ  rst report on 
SPRINT indicated lower hospital mortality rates and less 
hypoglycemia in long-stay protocol patients [11]. What 
does this mean for the reader and bedside clinician in the 
intensive care unit (ICU)?
Th   e Leuven I study unleashed a torrent of skepticism, 
excitement and investigation into tight glycemic control 
[2]. Google searches for ‘tight glycemic control’ and 
‘intensive insulin’ produce 80,900 and 334,000 results, 
respectively. After entering a new decade, where are we? 
Th   ere is a great deal that we do not know, in part because 
this ﬁ   eld of discovery has been disadvantaged by 
inconsistencies in research methodology. Among diﬀ  er-
ences in the studies are case-type selection, targeted 
ranges of blood glucose, inconsistency in the frequency 
of blood glucose monitoring, variability in the accuracy 
of glucometer devices used, variability in the methods 
used to deﬁ  ne euglycemia, whether insulin dosing was 
driven by paper protocol or software algorithm, and 
nonstandardization in caloric intake.
Starting with the Leuven I trial, all of the prospective 
studies conducted to date are vulnerable to signiﬁ  cant 
methodologic criticisms. We also really have no conclu-
sive understanding of the biologic plausibility to explain 
how intensive insulin would decrease death or organ 
failure or nosocomial infection – is it through anti-
inﬂ   am  matory pathways, or because insulin is a vaso-
dilator that may increase microperfusion, or by other 
unrealized mechanisms of action? In some ways, the 
scientiﬁ  c evolution of this ﬁ  eld resembles that of sepsis 
research from 1985 to 2005, in which the study of anti-
inﬂ  ammatory compounds was severely hindered by lack 
of standardization in the total treatment for patients with 
severe sepsis, with too many confounding and 
uncontrolled variables [12].
After all of these studies, what do we actually know? 
What are the consistent threads? Th  e following sum-
marizes what we know with certainty.
First, hyperglycemia is toxic. Falciglia and colleagues 
convincingly showed in an analysis of 259,040 ICU 
patients that hyperglycemia (glucose >6.1 mmol/l) was 
associated with mortality independent of illness severity, 
type of ICU or length of stay [13]. Consistent with the 
ﬁ   ndings of others, the two-thirds of patients who are 
nondiabetic beneﬁ  t more from insulin than do diabetic 
patients.
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© 2010 BioMed Central LtdHypoglycemia is also lethal. An incidental and constant 
observation from many studies is that severe hypo-
glycemia (glucose <2.2  mmol/l) in a population of 
patients by logistic regression is associated with a sixfold 
increase in death [14]. It would not be surprising to ﬁ  nd 
with additional study that even mild hypoglycemia has 
longlasting but subtle neurologic consequences that are 
not clinically evident or measured.
Th  ird, critically ill patients typically sustain wide 
deviations in blood glucose, even with insulin adminis-
tration [15]. Restricting the blood glucose within a target 
range in a hypermetabolic patient with changing gluco-
neo  genic drivers in a 24-hour day is enormously 
challenging, frequently outstripping the crude tools used 
at the bedside to measure blood glucose and to respond 
to its variation in concentration.
Software-driven insulin dosing is better than paper-
driven insulin protocols. Software integrates all of the 
glucose measurements and all of the previous insulin 
adjustments to determine the next best insulin dose. 
Software appears to reduce glucose variability and to 
sustain glucose within the target range for prolonged 
periods of time [16]. Th  ere are now many software 
programs tested and/or available.
Handheld blood glucometers, originally intended for 
use by type I diabetic outpatients in the 1980s, are not 
accurate enough in the ICU environment [17], and are 
very laborious to use. In March 2010, the US Food and 
Drug Administration hosted a public inquiry into 
glucometers, and is now redeﬁ  ning what it will accept 
regarding accuracy of blood glucose measurement 
devices in the hospital setting [18]. Th  e US Food and 
Drug Administration has asked the international 
standards body to reset its limits for accuracy for 
glucometers. Current-generation handheld devices now 
in use will not make the cut.
Finally, the more frequent the blood glucose measure-
ment, even with handheld glucometers, the less hypo  gly-
cemia experienced by patients and the tighter the glycemic 
control [19]. Th  e SPRINT study supports this premise. 
Frequency is crucial, however laborious it may be.
What can we expect going forward?
We can expect that the world will continue to use 
intensive insulin, but that the range deﬁ  ning tight glucose 
control will be narrowed as it becomes more achievable. 
We can expect that there will be more emphasis on 
deﬁ  ning hypoglycemia, and in avoiding it with greater 
rigor. We can expect a movement towards insulin-dosing 
software, as the development of many programs appears 
simple, and competition will force down the cost of 
purchase and use. Software insulin-dosing has hidden 
advantages: it forces more blood glucose monitoring and 
also provides an instant database for analysis. We will 
someday be using glucometers that are engineered to be 
more accurate, especially in the hypoglycemic range, 
avoiding pitfalls in today’s instruments due to chemical 
inter ferences  and  speciﬁ  c  disease  conditions. 
Importantly, these devices will be continuous or near 
continuous, will push blood glucose information to the 
bedside nurse and by their nature will be less arduous. At 
the same time, manufacturers will need to make these 
devices aﬀ  ordable, or their uptake will be slowed. Th  e 
greater frequency of blood glucose measurements by 
these devices will dramatically make safer the continuous 
administration of insulin.
Improving the accuracy of blood glucose measurements 
and standardizing the determination of insulin-dosing 
with better methods will produce better quality research, 
thereby synergizing global convergence on tight glycemic 
control, reduced glucose variability and better patient 
outcomes.
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